(VR) platelet (PLT) product with greater than 95% reduced plasma content and a 15-fold higher PLT concentration, potentially minimizing adverse reactions due to plasma, in particular for human leukocyte antigen (HLA)/human PLT antigen (HPA)-matched PLTs when minor ABO incompatibility cannot be ...
Compared to the ABO-compatible group, major/bidirectional mismatches had increased red blood cell (RBC) transfusion requirement during the first 100 days (p = 0.009), delayed RBC and PLT engraftment (p = 0.0011 and p = 0.005, respectively), and higher incidence of grade II to ...
(VR) platelet (PLT) product with greater than 95% reduced plasma content and a 15-fold higher PLT concentration, potentially minimizing adverse reactions due to plasma, in particular for human leukocyte antigen (HLA)/human PLT antigen (HPA)-matched PLTs when minor ABO incompatibility cannot be ...
Bu AUC, mg/L × hD until ANC >0.5 g/LD until PLT >50 g/L 1 XLP1/SH2D1A M 16 y Family history N NA CR N/IVIG MUD/10/10/BM Alemtuzumab 0.5 2.1 6.4 59 23 21 2 XLP1/SH2D1A M 22 y HLH episode, IgG low EBV-hepatitis/-CMP N 1040 CR Y/steroids MSD/6/6/PBSC ...
As for blood support, the median number of PC and PLT transfusions was 5 (range, 2-20) and 21 (range, 0-180), respectively. 18/22 (81.8%) pts achieved full donor chimerism at 1 month after transplantation (2 pts are too early to evaluate).Safety Overall Tevagrastim was found to ...